Lexicon is eligible to receive upfront and near-term milestone payments of up to $75 million. In total, Lexicon will be eligible to receive $1 billion in upfront and potential development, regulatory ...

Coverpla is nearing its 80th anniversary. Copyright © 2025 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, ...

ISLAMABAD: The Federal Board of Revenue (FBR) has directed manufacturers not to remove goods from their business premises unless production of finished products went through the process of ...

Blog posts represent the views of CFR fellows and staff and not those of CFR, which takes no institutional positions. Most of the major U.S. pharmaceutical companies (AbbVie, Amgen, Bristol Myers ...

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on aTyr Pharma (ATYR – Research Report) today and set a price target of $20.00. The company’s shares closed yesterday at $3.99.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The occasion was the 2025 PRWeek Healthcare Awards, a celebration of the sector that crafts the public’s perception of pharmaceutical ... banner emblazoned with logos of corporate sponsors.

With a thrust on strong operations over the past decade, Indian pharma production has outpaced global growth by over two times. Image: Sanjay Rawat India’s pharmaceutical sector is at a tipping point ...

For years, Jeff Simmons — the president and CEO of the large US pharmaceutical company Elanco — ridiculed a seemingly unlikely target on social media: the plant-based meat industry.

Recursion Pharmaceuticals showcased significant progress in advancing its pipeline and platform capabilities, supported by clinical data readouts and partnerships with Roche and Sanofi.

Opinions expressed are those of the author. 2025 is going to be a big year for AI adoption in pharma. By now, most life science companies have at least experimented with one generative AI (GenAI ...